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Background: Recent technological advances in epigenome profiling have led to an increasing 
number of studies investigating the role of the epigenome in obesity. There is also evidence 
that environmental exposures during early life can induce persistent alterations in the 
epigenome, which may lead to an increased risk of obesity later in life.  
Method: This paper provides a systematic review of studies investigating the association 
between obesity and either global, site specific, or genome-wide methylation of DNA. 
Studies on the impact of pre- and postnatal interventions on methylation and obesity are also 
reviewed. We discuss outstanding questions, and introduce EpiSCOPE, a multidisciplinary 
research program aimed at increasing the understanding of epigenetic changes in emergence 
of obesity. 
Results: An electronic search for relevant articles, published between September 2008 and 
September 2013 was performed. From the 319 articles identified, 46 studies were included 
and reviewed. The studies provided no consistent evidence for a relationship between global 
methylation and obesity. The studies did identify multiple obesity-associated differentially 
methylated sites, mainly in blood cells. Extensive, but small, alterations in methylation at 
specific sites were observed in weight loss intervention studies, and several associations 
between methylation marks at birth and later life obesity were found.  
Conclusions: Overall, significant progress has been made in the field of epigenetics and 
obesity and the first potential epigenetic markers for obesity that could be detected at birth 
have been identified. Eventually this may help in predicting an individual‟s obesity risk at a 
young age and opens possibilities for introducing targeted prevention strategies. It has also 
become clear that several epigenetic marks are modifiable, by changing the exposure in 
utero, but also by lifestyle changes in adult life, which implies that there is the potential for 
interventions to be introduced in postnatal life to modify unfavourable epigenomic profiles. 
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There is little contention that the rising incidence of obesity is a major public health issue 
world-wide 
1
. Obesity is a major risk factor for co-morbidities, such as type 2 diabetes, 
cardiovascular disease, and certain forms of cancer 
2
. Thus, the obesity epidemic threatens 
to reduce the length and quality of life of current and future generations, and it presents a 
significant challenge to future health care budgets. There is a strong need for safe and 
effective strategies for obesity prevention and treatment. A multitude of campaigns have 
been launched by governments and health agencies, but for the most part with limited 
effects on reducing obesity rates in the medium to longer term 
3
. Part of the reason for this 
failure could be that these strategies are typically introduced after obesity is established, 





focus of anti-obesity campaigns should therefore be on prevention in order to achieve 
maximum long-term health gains. To improve prevention and treatment strategies a better 
understanding of factors contributing to the development of obesity is essential.  
 
Epigenetics and human disease 
Over the last decade there has been increasing interest in the role of epigenetics in the 
development of complex conditions such as obesity. In contrast to genetic modifications, 
which lead to a change in the base sequence of DNA, epigenetic changes are typically 
reversible and refer to chemical modifications to DNA (or DNA-associated chromosomal 
proteins called histones) that occur in the absence of a change in the DNA sequence 
6
. 
Epigenetic marks are heritable through mitotic cell division and can alter the way the 
transcription of genes is controlled within a cell. This occurs through a number of processes, 
the best described being the addition of methyl groups to DNA (methylation) and 
posttranslational modifications to histone proteins, such as acetylation and methylation. 
©    2014 Macmillan Publishers Limited. All rights reserved.
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Methylation of mammalian genomes occurs predominantly at cytosines adjacent to guanines 
(„CpG‟ sites). Epigenetic processes alter the accessibility of the transcriptional machinery to a 
particular gene, thereby determining whether or not the gene is active in a given cell at a 
given time. Importantly, whilst the DNA sequence of genes in an individual (the genome) is 
largely stable, the epigenome has the potential to be reversibly modified by exposure to a 
range of nutritional and environmental factors 
6
.  
The importance of epigenetic processes in human disease was first identified in the field of 
cancer in the 1980s 
7
. Since then, there have been a plethora of studies that have described 
epigenetic changes in cancerous tissues, and in the blood of cancer patients, and alterations in 




More recently, the attention of the scientific community has turned to the potential role of 
epigenetic modifications in other disease states, including obesity. Initial studies were limited 
in sample size and number of CpG sites (CpGs) studied. With advances in technologies and 
the emergence of more affordable, high throughput methylation screening methods, there has 
been an increase in larger scale studies and the first epigenome wide association studies 
exploring the relationship between the environment, the epigenome and complex disease 
states. To date, DNA methylation, either at global, site-specific or genome-wide levels at 
single nucleotide resolution, is by far the most studied epigenetic mark. There have been few 
investigations of histone modifications in relation to obesity in humans, but some of the 
results to date do suggest an association between genome-wide histone modifications and the  
development of or susceptibility towards obesity 
9
. 
There is accumulating evidence that the propensity toward adult obesity has early 













studies have shown that exposure to a suboptimal nutritional environment during 
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development, as a result of either an excess or deficient maternal caloric or micronutrient  
intake, is associated with an increased risk of a range of chronic diseases,  including obesity, 










. These findings have led to 
the developmental origins of health and disease (DOHaD) hypothesis, which proposes that 
adult disease risk can be programmed by the perinatal environment 
21
.  
One consistent theme relating to this hypothesis is that transient environmental influences 
experienced early in life can cause permanent effects that emerge as increased disease risk 
much later in life. The mechanisms underpinning this nutritional „memory‟ response are not 
clear but may include changes in the developmental trajectories of tissues, reprogramming of 
stem cells, changes in tissue structure, and the reprogramming of neural, endocrine and 
metabolism regulatory circuits. Epigenetic programming may be mechanistically involved in 
these processes or provide a readout of their occurrence. Moreover, once established, early 
life nutritionally-induced epigenetic changes may lie dormant until their biological influence 
is triggered later in life. 
Evidence to support a role of epigenetics in developmental programming of disease has been 
predominately derived from animal studies that have demonstrated the impact of a 









. There are relatively few human studies in this area, but one of the most 
significant studies was conducted in children who were born to women exposed to severe 
undernutrition during pregnancy as a result of the Dutch Hunger Winter during World War II, 





. This has particular relevance given that these individuals have also been shown to 
be at increased risk of obesity or glucose intolerance, depending on the timing of the 
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In this review we provide a systematic overview of the most recent findings in the research 
area of epigenetics and obesity, specifically focused on human studies. Studies investigating 
the association between either global methylation, site specific methylation, or genome-wide 
methylation of DNA and obesity, are summarized and discussed. In addition, the impact of 
interventions on DNA methylation profiles and obesity in children are summarized. 
Moreover, it discusses outstanding questions and introduces EpiSCOPE, a multidisciplinary 
research program with the goal of increasing the understanding of epigenetic changes in 
emergence of obesity. 
 
METHODS 
The MEDLINE database was searched for relevant studies published between September 15, 
2008 to September 15, 2013, using the search terms “obesity OR body mass index OR 
overweight OR body fat OR adiposity OR adipose tissue” AND “epigenetics OR methylation 
OR histone”. The first search was restricted to primary studies in humans, and an additional 
search was performed for articles that were not labelled as a human or animal study. The 
titles and abstracts, and in several cases the full texts, were scanned to determine their 
relevance to the scope of this review. Studies to be included either described an association 
between epigenetic marks and obesity in humans or reported an effect of a defined 
intervention on epigenetic marks and obesity in humans.  
 
Studies Identified by Search Strategy  
From the 319 articles identified by the search strategy, 273 articles were excluded; 55 papers 
were reviews or commentaries, rather than original research articles, 62 studies were not 
conducted in humans, 71 did not assess any outcomes related to obesity, 18 did not assess an 
epigenetic outcome, 32 included only in vitro data and 35 were excluded for other reasons, 
©    2014 Macmillan Publishers Limited. All rights reserved.
9 
 
(e.g. methodology studies, or studies which included individuals with hereditary diseases or 
cancer). Thus, a total of 46 articles were included in this review. 
 
RESULTS 
Summary of included studies 
Of the 46 studies included, 15 studies assessed relationships between measures of obesity and 
global DNA methylation, 13 studies assessed relationships with DNA methylation in specific 
candidate genes, five studies used genome-wide approaches to assess differences in 
methylation between obese/lean individuals or the association with obesity measures, eight 
studies assessed DNA methylation profiles in relation to weight loss interventions and nine 
studies assessed relationships of DNA methylation at early life with either parental health 
measures or later life health outcomes. 
 
Global methylation and obesity 
Global methylation refers to the overall level of methyl cytosine in the genome, expressed as 
percentage of total cytosine (%5meC). A lowered global methylation level has been 
associated with chromosomal instability and increased mutation events and is considered as a 
hallmark of cancer 
31
, but less is known about global methylation in other disease states.  
Repetitive elements, such as ALU and Long Interspersed Nucleotide Element 1 (LINE1), 
comprise ~50% of the genome and the degree of methylation in these elements is often used 
as a surrogate to represent the overall methylation level of the genome. Because of the 
relatively low cost and high throughput, global methylation levels are reasonably easy to 
determine in large numbers of samples, which makes it ideal for screening purposes.  
Details of the 15 studies that have examined global methylation in relation to obesity are 
summarised in Table 1. The majority of the studies used blood samples, but LINE1 
©    2014 Macmillan Publishers Limited. All rights reserved.
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methylation in DNA from muscle, placenta and colon has also been studied. All of the studies 





. The majority of these investigations, including a large study combining four study 
populations, including up to 1254 individuals 
34
, did not find an association between obesity 
and global methylation
33,35–40




, found reduced 
global methylation with increasing BMI, however in one of these studies this only occurred 
in the presence of low concentrations of the methyl donor folate 
32
. In contrast, two other 
studies that included both men and women from two different populations (Samoa and 
China) reported a positive relationship between global methylation in Peripheral Blood 




, and in a further study global methylation in placental 
tissues was higher in obese compared to lean women 
40
. Only one study examined global 
histone methylation in obesity, showing substantially decreased levels of histone H3 lysine 4 
dimethylation in adipocytes of overweight individuals compared with lean, with increased 
levels of lysine 4 trimethylation, observed in obese/diabetic individuals 
9
. Thus, while some 
studies do report significant associations between global methylation and obesity-related 
measures, the direction of change is not consistent, and both global hypomethylation as well 















There are a multitude of factors, including gender, ethnic background, age, exposure to 












, that are known to affect global 
methylation levels, which could influence a potential association between global methylation 
and obesity. In several studies corrections for at least a few of these confounding factors have 
been applied, but often not all confounding factors are known and  taken into account.  
Overall, the available global methylation studies in obesity do not provide consistent 
evidence for a relationship between global methylation and obesity. Compared to the 
situation in cancer, global methylation changes in obesity (if present) are likely to be more 
©    2014 Macmillan Publishers Limited. All rights reserved.
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subtle and thus difficult to detect considering the influence of multiple other factors on this 
measure. Consequently, more specific methylation analyses, either for specific loci of interest 
in obesity, or a genome-wide approach are likely to provide a better picture of the association 
between obesity and DNA methylation. Larger sample sizes (>1000) may also be required to 
produce more robust results. In addition, the studies that have been conducted to date point to 
the potential for sex differences in the relationship between BMI and global methylation, 
which also require further investigation and suggest that it is important to examine 
associations separately in males and females. 
 
Gene-specific DNA methylation and obesity 
The epigenetic environment of individual genes provides a critical component contributing to 
their regulation and level of expression. Because of the relative ease of analysis, gene-
specific DNA methylation is the most extensively studied epigenetic mark in studies relating 
epigenetic changes to health outcomes, including obesity. Historically, elevated DNA 
methylation has been associated with repression of gene expression. However, with the 
advent of genome-wide methods of DNA methylation analysis, it is now recognized that the 
association of DNA methylation with gene expression is not as simple as previously thought, 
and appears to depend on where within the gene sequence the methylation occurs. In general, 
DNA methylation at gene promoters and enhancers is associated with gene silencing and 
higher methylation in the gene body with active gene expression, but even this is an 
oversimplification 
50
.    
The majority of studies examining the relationship between site-specific DNA methylation 
and obesity are cross-sectional; i.e. both methylation levels and the phenotype are measured 
at the same time point. Hence it cannot be established whether the association between a 
©    2014 Macmillan Publishers Limited. All rights reserved.
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specific DNA methylation mark and obesity is a cause or a consequence of the obese 
phenotype.  
 
Candidate gene studies 
Multiple studies have used a hypothesis driven, candidate gene approach (summarised in 
Table 2) where methylation sites in, or near, known candidate genes for obesity 
susceptibility, have been the subject of investigation. In some cases the choice of genes has 
been based on prior analysis of gene expression differences in the same subjects. The 
candidate gene methylation studies have focussed on a range of genes implicated in obesity, 
appetite control and/or metabolism, insulin signalling, immunity, growth, circadian clock 
regulation and imprinted genes, and assessed their relationship with a variety of obesity 
markers. Collectively, these studies have identified lower methylation of tumour necrosis 
factor alpha (TNFα) in PBL  51, pyruvate dehydrogenase kinase 4 (PDK4) in muscle 52 and 
leptin (LEP) in whole blood (WB) 
53
 and increased methylation of proopiomelanocortin 
(POMC) in WB 
54
, PPARγ coactivator 1 alpha (PGC1α) 52 in muscle, and CLOCK and aryl 
hydrocarbon receptor nuclear translocator-like (BMAL1)
55
 genes in PBL in obese compared 
to lean individuals. Associations between BMI, adiposity, and waist circumference, with 
methylation in PDK4 in muscle
52
, melanin-concentrating hormone receptor 1 (MCHR1) in 
WB 
57
, and the serotonin transporter (SLC6A4) gene 
56
, the androgen receptor (AR) 
58
, 11 b-
hydroxysteroid dehydrogenase type 2 (HSD2) 
59
, period circadian clock 2 (PER2) 
55
 and 
glucocorticoid receptor (GR) 
59
 in PBL have also been reported. The most consistently 
observed epigenetic association has been that of methylation at the IGF2/H19 imprinting 




. Collectively, these studies provide 
evidence that obesity is associated with altered epigenetic regulation of a number of 
metabolically important genes.  




Genome-wide analyses and obesity 
The recent development of genome-wide methods for quantifying site-specific DNA 
methylation has led to the initiation of studies that are not targeted to specific genes, but 
search for associations across a large number of genes and CpGs. Obesity-associated 
differentially methylated (DM) sites in peripheral blood cells were detected in four published 








. Extensive, but small, alterations in methylation at 
specific sites have been observed. In one case a signature of DM sites was used to predict 
obesity in a validation set 
62
, while in other studies specific DM CpGs were validated in a 
second cohort 
63
, or at a second time point 
64
. 
Overall, obesity associated DM sites were enriched both in obesity candidate genes 
62
 and in 





 and regulation of transcription 
61
. DM sites were also identified in or near 
genes with no known function related to obesity or adipose tissue functioning.  
 
Intervention studies in adults 
It has long been assumed that DNA methylation profiles would remain stable throughout 
adult life; however, this view is now changing. Interventions such as exercise, diets and 
weight loss surgery have been shown to modulate methylation profiles in different tissue 






. Interestingly, methylation profiles of obese individuals became more 
similar to those of lean individuals following weight loss surgery 
52
. Although this was only 
demonstrated in a small study, it suggests that methylation profiles of obese individuals can 
be modified by reductions in body weight/fat mass. This conclusion may imply that some 
methylation marks are a consequence of the obese phenotype, rather than a programmed 
mark that predisposes people to become obese. These findings again highlight the importance 
©    2014 Macmillan Publishers Limited. All rights reserved.
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of studies in which methylation marks are measured early in life before disease manifests, to 
define which acquired marks become permanent, and thus potential early markers for disease 
risk, and which ones are semipermanent and modifiable in later life. 
 
In a separate group of studies, comparison of the methylation profiles of people who 
successfully lost weight during interventions and those who did not, has been used in order to 
determine whether there may be biomarkers that predict individual responsiveness to weight-










. Methylation differences between these individuals 
were identified in genes involved in weight control, insulin secretion, inflammation, and 
circadian rhythm. The association of such methylation differences with a propensity to lose 
weight may imply that methylation changes in those genes predisposes individuals to become 
and stay obese, even in situations of limited food intake. Adherence to the interventions was 
monitored in most studies through regular meetings with study dieticians, or attendance at 
group exercise or therapy sessions.  However, it is notoriously difficult to accurately monitor 
compliance in nutritional intervention studies in humans, and it is therefore possible that 
failure to lose weight might also be a reflection of poor adherence of the participants to the 
intervention. 
 
Prenatal and postnatal environment  
The period of embryonic development has been recognised as a critical window in the 
establishment of the epigenome. There is compelling evidence that an adverse pre-natal and 








  and this has led to 
the search for nutritional interventions during pregnancy and lactation which have the 
potential to mitigate or overcome this adverse programming 
12
. Diet and weight loss 
interventions in obese mothers may lead to a decreased risk of obesity in the offspring, 
©    2014 Macmillan Publishers Limited. All rights reserved.
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possibly mediated through changes in insulin signalling, fat storage, energy expenditure or 
appetite control pathways. Epigenetic mechanisms are likely to play a role in this altered risk 
profile and the findings of obesity associated methylation marks in genes involved in these 
processes also support this hypothesis. Human studies showing a direct relationship between 
specific prenatal (nutritional) exposures on methylation profiles of the offspring and 
subsequent risk of obesity in later life are scarce. However, there are a number of studies 









 or have explored relationships between epigenetic 
markers in the cord blood at delivery and obesity/metabolic outcomes in childhood  (Table 
4). One such study compared methylation profiles of siblings born before and after maternal 
weight loss surgery, and reported differences between the siblings in obesity characteristics 





, some of which translated into alterations in gene expression and 
insulin sensitivity. Although this was a small study, its findings suggest that significant 
weight loss, and presumably improved metabolic health profiles, in the mother are associated 
with a distinct epigenome and lower weight and waist circumference in the children.  
Additional studies have explored the association of DNA methylation at birth with adiposity 








. Methylation variation in the promoter of the retinoid X 
receptor alpha gene (RXRα) in umbilical cord tissue was found to explain up to 26% of the 
variation in childhood adiposity 
79
. RXRα is a nuclear receptor with a known role in 
adipogenesis 
82
; it forms a heterodimer with the transcription factor PPARγ to activate 
transcription of genes involved in adipocyte differentiation, glucose metabolism, 
inflammation and energy homeostasis. DNA methylation appears to be also important in the 
regulation of PPARγ 83, and variation in DNA methylation of PGC1A, interacting with 
PPARγ, has been associated with weight loss, obesity, and risk for T2DM 52 84 85. Variation in 
©    2014 Macmillan Publishers Limited. All rights reserved.
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methylation within tumour-associated calcium signal transducer 2 (TACST2) at birth was also 
found to correlate with fat mass in later life, however, further analysis including Single 
Nuclear Polymorphism data of this gene showed that reverse causation or confounding was 
likely to account for the observed correlation 
81
. IGF2 is another example of a gene showing 
loci-specific variation in methylation at birth, and also at childhood, that is associated with 






. The epigenetic regulation of IGF2 has 
been of particular interest given its role in control of fetal growth and development. 
Differences in the degree of methylation near IGF2 has often been linked to exposure to a 








. Contradictory findings, however, come from 




The finding of an association between variation in matrix metallopeptidase 9 (MMP9) 
methylation levels  at birth and childhood adiposity 
80
  is also of interest, given the critical 
role that metalloproteinases play in extra cellular matrix remodelling during adipose tissue 
formation, and coupled with the fact that altered MMP9 plasma levels and gene expression 
has previously been found in obese individuals 
88
. Moreover, variation in methylation near 
MMP9, and another metalloproteinase called PM20D1, was associated with BMI in a 
genome-wide study, at two time points 11 years apart 
64
. These findings show that these 
marks are most likely established at an early age and may be associated with adiposity at 
different stages in later life, which suggests that these methylation changes could be 
potentially useful to predict obesity risk from an early age.  
  




Measurement of DNA methylation 
The advent of genome-wide, array-based methods for determining site-specific DNA 
methylation is opening a new window for identifying phenotype differentially methylated 
sites or regions. An overview of different methods of DNA methylation analysis and 
discussion of their respective advantages and disadvantages, including those used in the 
reviewed studies, can be found in supplementary table 1. While a number of technologies 
have been used to date, the Illumina Infinium Methylation450 bead Chip is emerging as the 
most widely used platform. Early experience suggests that the technology provides 
reproducible quantitative data and its widespread use will facilitate cross-study comparisons. 
Since assessment is made of only a selected set of CpGs and regions (<5% of total number of 
CpGs), it will be important that other technologies that explore the genome more widely 
continue to be used.  
Notably, both from candidate gene and genome-wide approaches, the methylation differences 
associated with obesity or interventions reported to date have generally been small. In array-
based approaches, since the number of individuals is low compared to the high number of 
sites measured, often only a few DM sites remain significant after strict multiple testing 
corrections. The presence of co-ordinate variation at CpGs within a localised region can 
provide more confidence that differences seen are real and methods looking at variable 
methylated regions, as opposed to single sites, are increasingly being used in analysis of 
methylation data to overcome the problems associated with strict multiple testing corrections 
89
. It has been proposed that particular regions of the genome show high levels of variance in 
methylation levels and that this might provide potential for gene expression levels to stably 
respond to environmental conditions 
90
.   This adaptability would confer a significant fitness 
advantage and has probably been subject to strong selection during the longer time scales of 
©    2014 Macmillan Publishers Limited. All rights reserved.
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evolution, i.e. the genetic blueprint has likely been altered by evolution and natural selection 
to enhance epigenetically mediated adaptability traits. In support of this a significant overlap 
in variably methylated regions and DM regions has been observed 
62
. Given the modest levels 
of change in DNA methylation, it is expected that the effect size on phenotype of individual 
DM sites is generally likely to be small. However, it is noteworthy that methylation at the 
RXRA locus at birth could statistically account for 26% of variation in adiposity of children 
at 9 years
79
.  Similar to genetic variations, it will probably not be one single DM site but more 
likely combinations of multiple (in)dependent DM sites, possibly in several genes, that can 
explain variations in phenotype and that will need to be used in combination to develop 
predictive signatures.  
 
The vast majority of epigenetic studies published to date focused only on DNA methylation, 
thereby ignoring other epigenetic information, such as histone modifications and non-coding 
RNAs. Histone modifications can influence DNA methylation patterns and vice versa, and 
there is evidence that histone modifications play key roles in adipogenesis 
91
. Thus, these are 
likely to have an important role in the development of obesity and should be taken into 
account in epigenetic studies.  Integration of epigenome and transcriptome data will also be 
crucial to obtain a more complete picture of the interaction between epigenetic modifications 
and regulation of gene expression.  
 
DNA methylation in different tissue types 
DNA from peripheral blood cells is the most frequently used source of DNA for epigenetic 
studies. Since blood is easily accessible, it is often the only biological material that is 
routinely sampled in large scale studies. A potential issue with the use of blood is that it 




. It has 
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However, if one wants to minimize potential effects of cellular heterogeneity on methylation 
profiles, a correction based on the numbers of each respective cell type in the sample may 





Another important consideration when using blood in epigenetic studies is that the blood cell 
methylation profile in blood may not necessarily report the epigenetic state in other tissues. 
Since the hematopoietic system is established very early in development, it has been 
suggested that methylation changes induced around conception and in early embryo 
development may be reflected in all germ layers and thus detectable in blood and most tissue 
types 
64
. Later in development, however, environmentally induced epigenetic changes might 
be more tissue specific and may not be detectable in blood. A recent study comparing 
methylomes across 30 human tissues and cell types showed that there is a large „common 
methylation profile‟ across tissues and only a small fraction (~20%) of CpGs show dynamic 
regulation during development 
100. Efforts to provide a “Blue Print of Human Epigenomes”, 
as undertaken by consortia like International Human Epigenome Consortium (IHEC), will be 
of considerable value to get a better insight in tissue specific epigenetic signatures and their 
role in disease development.  
 
To increase our understanding of the role of epigenetics in obesity, adipose tissue is of high 
interest. Adipose tissue is not only the main tissue for energy storage, but also has important 
endocrine functions which are often disrupted in obesity. Adipose tissue contains functionally 
different cellular subtypes and different depots have distinct characteristics depending on 
their anatomical location. Metabolic disturbances are often linked to increased fat deposition 
in visceral depots, while storage in subcutaneous depots is considered less problematic from a 
©    2014 Macmillan Publishers Limited. All rights reserved.
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metabolic stand-point. Recently, there has been renewed interest in understanding the role of 
brown fat in humans, in particular in relation to human obesity, as a consequence of its fat 
burning properties 
101
. Since DNA methylation is of major importance in defining cellular 
identity and differentiation of adipocytes, the study of DNA methylation profiles in different 
adipose tissue depots under different metabolic conditions could provide information about 
how epigenetic regulation of adipose tissue is involved in the development of obesity and 
associated co-morbidities, and how this could potentially be manipulated. Studies have 
already shown that DNA methylation in adipose tissue can change after exercise intervention 







which indicates that epigenetic regulation in this tissue is likely to be of importance and 
should be further investigated.  
For diagnostic purposes in a clinical setting, particularly when screening young children, 
epigenetic marks should be detectable in easily accessible samples, such as peripheral blood, 
or possibly buccal cells. Blood and buccal cells originate from different germ layers and the 
degree of similarity in methylation between both tissues varies across the sites that have been 
examined so far. An extensive comparison of genome-wide methylation profiles in both 
tissues has not yet been done and would be of significant interest to the field. 
For screening at birth, DNA isolated from the umbilical cord might also be of interest, 
especially in light of the findings that variation in methylation in this tissue is highly 
associated with body fat mass in later life 
79
. Cord blood and newborn blood spotted on filter 
paper (Guthrie cards) are other relatively accessible materials. Guthrie cards are routinely 
collected worldwide for screening of  genetic diseases in newborns and a number of studies 





. In countries where these samples are routinely stored for 
extended periods of time, they provide a unique resource for researchers to determine 
©    2014 Macmillan Publishers Limited. All rights reserved.
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whether specific methylation marks detected at older ages were already present in the 
individuals at birth. 
 
Stability and inter-individual variation in DNA methylation  
When considering methylation marks as biomarkers for disease risk, it is essential that they 
show substantial variation between individuals, and are relatively stable over time. For the 
design and interpretation of epigenetic studies, it is also important to know the actual scale 
and extent of inter-individual variation in DNA methylation. 
Variability in DNA methylation across healthy individuals is a combination of genetic 




. A number of studies have 
investigated the stability and inter-individual variation in DNA methylation, mainly in blood, 
comparing changes in DNA methylation profiles over short time spans (days) to longer 
periods (years). The period from birth to childhood is considered a dynamic period for DNA 
methylation; Wang et al. showed that methylation status of 5% of the measured 27,000 
CpGs substantially changed from birth to two years of age 
105
 and in another study ~8% of 
the sites on the Illumina arrays showed age-associated methylation in childhood 
106
. Multiple 
studies have demonstrated that some methylation marks show considerable variation over 








. It has been suggested that the stable epigenetic 
marks represent those determined by genetics, while the variable marks are more likely to be 
influenced by the environment 
64
. A comparison of methylation profiles between populations 
of different ethnic backgrounds showed that about two-thirds of population-specific CpGs are 
associated with genetic background 
104
, while one-third might be influenced by other factors. 
 
The stability and inter-individual variation in methylation is also dependent on its genomic 
location. Low levels of inter-individual variation have been found at commonly unmethylated 
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regions such as CpG islands, and higher variation is measured in regions adjacent to the CpG 








. DM regions also show enrichment of Single 
Nucleotide Polymorphisms (SNPs), which may help explain why several DMRs were found 
within or near obesity candidate genes. DNA methylation at sites that associate with SNPs 




. In this regard 
the presence of SNPs that are associated with cis-acting regional changes in DNA 
methylation status are of particular interest 
113
.   
 
Study design and analysis 
Robustly designed, well-conducted and adequately powered studies are crucial for the 
identification of early epigenetic biomarkers (whether causative or not) for obesity risk and in 
establishing the effects of the in utero environment.  
 
Cross sectional studies 
In most current studies, methylation levels and the phenotype are measured at the same time 
point, which makes it impossible to define whether specific DNA methylation marks are a 
cause or consequence of obesity. However, while they may not be contributing to the etiology 
of obesity they may still be useful for predicting obesity risk. The association between 
methylation and obesity may be indirect; there is most likely a third factor (nutritional or 
environmental) involved that independently affects both methylation and obesity.  
Where no longitudinal data is available, statistical approaches have been developed in 
epidemiological studies to infer causality and these are beginning to be applied to epigenomic 
data. For example, Liu et al. inferred that methylation at specific sites mediated genetic risk 
for rheumatoid arthritis 
98
.  The Mendelian randomisation strategy, as proposed by Relton and 
Davey Smith 
114
, makes use of SNP data as a proxy for DNA methylation and the modifiable 
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exposure of interest, and may be a useful approach to gain a better understanding of the 
direction of causality. However, this approach also has its limitations, and suitable SNP data 
are not always available. 
 
Longitudinal studies 
While an effect of early nutritional exposures on later life disease risk in humans has been 
demonstrated, evidence showing involvement of epigenetic processes in linking early 
nutritional exposure to later obesity risk in humans is scarce. To successfully address this 
knowledge gap, large randomised controlled trials and prospective studies will be needed.  It 
may not be ethical to conduct a randomized trial in all situations (e.g. restricting 
breastfeeding or randomly assigning children to be breast or formula fed). However, in the 
case of nutritional interventions applied during pregnancy, adequately powered randomized 
controlled trials are the only way to clearly dissect out the impact of the specific nutritional 
intervention from those of other environmental/demographic variables. In addition, in 
longitudinal studies, extensive data on parental phenotype and lifestyle, as well as parental 
blood or buccal cell samples, should ideally be collected before birth, and the phenotype and 
epigenome of the offspring should be followed prospectively from birth throughout their life 
course. Since DNA methylation profiles at birth have not been affected by postnatal 
environment or disease state in later life, such studies will provide better support for a link 
between early epigenetic marks and disease risk than cross-sectional studies. Another 
advantage of longitudinal studies is that genotype is constant and its direct effects on 
methylation profiles can be measured and removed. In addition, these studies may provide 
information on the dynamics of methylation changes during life time, this may help in 
identifying at what point during development an intervention would be most effective. 
Animal studies will also remain essential, particularly to give more mechanistic insight and 
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answer outstanding questions related to the underlying biology that are impossible to address 
in humans. 
Human and animal data suggests that not only maternal health and diet might be of 
importance for the offspring; there are also indications that the paternal contribution to 





Cohorts including multiple generations, siblings, or ideally monozygotic twins discordant for 
obesity, would be valuable in unravelling the impact of genetics and environment on the 
epigenome and phenotype. These types of studies are expensive and time consuming, but 













EpiSCOPE (Epigenome Study Consortium for Obesity primed in the Perinatal Environment) 
is a recently initiated multi-institutional Australian research program that aims to add 
valuable new information to our understanding of the role of epigenetics in the aetiology of 
obesity. The research will centre around three areas; 1) The epigenome of human adipocytes; 
EpiSCOPE will develop high resolution epigenome and transcriptome maps of visceral and 
subcutaneous adipocytes of healthy, lean individuals for comparison with obese and 
obese/diabetic subjects. Cross-tissue comparisons will be performed to establish the 
translatability of epigenetic patterns in adipocytes to blood.  2) Early epigenetic marks for 
obesity and the effect of in utero fish oil exposure; this study is utilising blood samples 
collected both at birth and during childhood from children from the large randomized 
controlled DOMInO trial 
120
  that provides the opportunity to investigate both the relationship 
of epigenetic marks to childhood metabolic outcomes and the effect of in utero fish oil 
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exposure on the development of childhood obesity and to determine whether epigenetic 
changes are involved in mediating this.  3) The effect of periconceptional obesity, without the 
presence of obesity during pregnancy, on the epigenome of the offspring. A sheep model was 
chosen because of the similarities in the prenatal development of many organ systems, 
including adipose tissue, in sheep and humans. The model will be used to investigate the 
molecular mechanisms in specific organs involved in risk of obesity and that contribute to the 
transmission of a vulnerability to obesity in the offspring of obese mothers.  
Using this three-pronged approach, EpiSCOPE aims to improve our understanding of the role 
of epigenetics in determining long-term metabolic outcomes and to provide an evidence base 
for the development of novel therapeutic and diagnostic targets to lower the burden and risk 
of a dominant chronic and to date intractable disease. 
 
FUTURE DIRECTIONS 
Overall, significant progress has been made in the field of epigenetics and obesity, but there 
is still much to be learned before we fully understand the role of the epigenome in 
development of complex diseases such as obesity. Epigenetics is a rapidly evolving area of 
research and the first steps are already being made in identifying potential biomarkers for 
obesity that could be detected at birth. Eventually this may help in predicting an individual‟s 
obesity risk at a young age, before the phenotype develops, and opens possibilities for 
introducing targeted strategies to prevent the condition. It is also now clear that several 
epigenetic marks are modifiable, not only by changing the exposure in utero, but also by 
lifestyle changes in adult life, which implies that there is the potential for interventions to be 
introduced in postnatal life to modify or rescue unfavourable epigenomic profiles. 
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Table 1 Global DNA methylation and risk factors associated with obesity 
Obesity 
measure





BMI PBL M and F, elderly (n=126) ↔ 35
LINE1
BMI PBL M and F, middle-aged (n=161) ↔ 33
BMI PBL F, Premenopausal (n=470) ↓ 32 Only in presence of low folate
BMI PBL M and F, adults, Samoan (n=355) ↑ 42
BMI PBL M and F, combination of 5 studies (n=1465) ↔ 34 In separate studies also no effect
BMI PBL M and F, middle-aged (n=228) ↔ 36
BMI PBL M and F, adults (n=165) ↓ 37 In multivariate linear regression 
BMI Lymphocytes F, obese, premenopausal (n=173) ↔ 38
BMI Placenta F, pregnant (n=50) ↑ 40
BMI Cord blood F, pregnant (n=50) ↔ 40
BMI Colon M and F, middle aged, previous adenoma 
(n=388)
↔ 39




Muscle M and F, monozygotic twin pairs discordant 
for T2DM (n=11)
↑ 84 Intra-pair differences in methylation 
associated with intra-pair differences 
in BMI
BF % PBL M and F, middle-aged overweight (n=161) ↔ 33 
BF % PBL F, premenopausal (n=470) ↓ 32 Only in presence of low folate
ALU
BMI WB F, postmenopausal (n=323) ↓ 41
BMI PBL M and F, Chinese (n=286) ↑ 43 Combined measure of methylation in 
ALU and SAT2 repetitive elements
BMI PBL M and F, adults (n=1254) ↔ 34 Combination of 4 studies, in separate 
study populations also no association
H3K4me2
BMI Adipocytes F, elderly (n=14 lean, n=19 overweight) ↓9 Decrease of 40%
H3K4me3
BMI Adipocytes F, elderly (n=14 lean, n=19 overweight) ↔ 9 No change in obese subjects, but 
increase in obese/diabetic subjects
H3K9me2
BMI Adipocytes F, elderly (n=14 lean, n=19 overweight) ↔ 9
Abbreviations: %5meC, Percentage 5-methylcytosine;  BF%, Body Fat Percentage; H3K4me2, histone H3 lysine 4 dimethylation;  
H3K4me3, histone H3 lysine 4 trimethylation; H3K9me2, histone H3lysine 9 dimethylation; 
PBL, Peripheral blood leukocytes; T2DM, type 2 diabetes mellitus. 
* ↑ Positive association with DNA methylation and health outcome. ↓ negative association with DNA methylation and health outcome. 
↔ no association with DNA methylation and health outcome
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Table 2 Specific gene methylation and obesity: Candidate gene and genome wide approaches 
Study design and 
reference
Population Tissue type Methylation sites/ method Main findings
Comparison of subjects 
with low vs high central 
adiposity. Association 
with BF% and BMI 51
Lean young 
women (n=40)
PBL TNFA  promoter, 20 CpGs/ 
Sequenom EpiTyper 
MassARRAY
Higher methylation levels of 2 CpGs in subjects with low 
compared to high central adiposity (7.1±1.8% vs 4.7±1.6 
%, P<0.001). Higher methylation levels in these CpGs 
were also associated with lower BMI (r=-0.38, P=0.015) 
and BF% (r=-0.34, P=0.034)
Association with BMI 53 Children 17 
months (n=120)
WB LEP , 10 CpGs in 7 CpG units 
/ Sequenom EpiTyper 
MassARRAY 
A 0.8% decrease in overall absolute LEP  methylation 
level was associated with a 1.3 kg/m2 increase in BMI 
(P=0.043)




WB IGF2/H19  ICR 12 CpGs in 6 
CpG units/ Sequenom 
EpiTyper MassARRAY
A 5.1% (males) and a 5.0% (females) increase in average 
IGF/H19  methylation level was associated with a 2.5 mm 
(males) and a 2.0 mm (females) increase in abdominal 
skin fold thickness (P=0.04 to 0.001). Average 




morbidly obese subjects. 








PBL CLOCK (39  CpGs, 2 regions), 
BMAL1  (26 CpGs), PER2  (27 
CpGs)/ Sequenom EpiTyper 
MassARRAY
Lean individuals, compared to morbidly obese 
individuals, had different methylation levels in multiple 
CpGs in the CLOCK  gene (CpG1: 2.4±0.6% vs 
1.1±0.2%, CpG5-6: 17.4±0.9% vs 12.4±0.7%, 
CpG8:10.8±0.8% vs. 8.7±0.8%, CpG 11-14 (49.5±2.7% 
vs 59.5±4.0%)), and lower methylation levels in 6 CpGs 
in BMAL1 . Associations between methylation levels of 
multiple CpGs in CLOCK, BMAL1 , PER2  and BMI, 
BF% and WC (r=-0 440 to 0 531 P=0 042 to <0 001)
Association with obesity 
characteristics 59
Adults (n=34) PBL HSD2, GR, IGF2  (DMR0, 
DMR2) and H19  (ICR)/ 
Pyrosequencing 
Positive association of methylation at several CpGs within 
HSD2, GR  and IGF2  and WC and BMI (partial r= 0.42 
to 0.57, P= 0.007 to 0.04)
Association with BMI 37 Adults (n=165) PBL IL-6 promoter, 6 CpGs/ 
Pyrosequencing 
No association found
Comparison lean and 
obese 54
Lean (n=36) and 
obese (n=71) 
adolescents. 
Validation in 2nd 
cohort of children 
(n=154)
WB POMC , 2 CpG islands in 5’-
promoter region and around 
the intron 2 and exon 3 
boundary/bisulfite sequencing 
A lower overall methylation score in lean compared to 
obese adolescents (25% vs 40%, P<0.001) in a region 
adjacent to an intronic Alu element in the POMC  locus. 
Highest difference between groups at a CpG at position 
+1 (methylation in 5% of lean children, but in 55% of 
obese children)




PBL SLC6A4 promoter region, 20 
CpGs/pyrosequencing 
On average, a 1% increase in mean methylation level was 
associated with a 0.33 kg/m2 increase in BMI (95% CI: 
0.02-0.65; P=0.03) and 0.78cm increase in WC (95% CI: 
0.05-1.50; P=0.03). Intra-pair differences in methylation 
level were correlated with intra-pair differences in BMI 
and WC at multiple CpGs. 
Association with BMI for 
different alleles MCHR1 57
Adults (n=39) WB MCHR1 , 2 CpGs in SNPs and 
15 additional CpGs/ Bisulfite 
specific PCR 
Methylation status of the GT allele is negatively 
associated with BMI (r=-0.814, P=0.024) 
Comparison MZ twins 
discordant for BMI 121
MZ twins (n=16) 
adults, discordant 
for BMI 
Saliva 20 CpGs in 9 growth-related 
imprinted regions/single 
nucleotide extension on 
bisulfite converted DNA (MS-
SNuPE)
Mean methylation indexes were very similar among co-
twins, no associations of intrapair methylation and BMI 
differences 
Association with BMI 58 Elderly men 
(n=170)
PBL AR  promoter,  8 CpGs in 5 
CpG units/ Sequenom 
EpiTyper MassARRAY
Methylation status of 1 CpG unit in AR  promoter was 
positively associated with BMI (r=0.24, P<0.05) and BF% 
(r=0.16, P<0.05) after adjustment for cell type variation in 
methylation
Association with BMI 52 Obese (n=8) and 
matched lean (n=9) 
women
Muscle PGC1 α and PDK4  promoter 
region/Bisulfite sequencing 
Methylation levels of PGC1 α were positively correlated 
(r=0.423, P=0.048), and methylation levels of PDK4 were 
negatively correlated (r=-0.707, P<0.001) with BMI





WB 1505 CpGs/ llumina 
GoldenGate Methylation 
Cancer Panel I
Without multiple testing corrections 27 CpGs were 
nominally associated with WC and 12 CpGs with BMI, 
some in genes with role in obesity and diabetes. None 
significant after multiple testing corrections
Comparison lean and 
obese 62
Lean (n=48) and  
obese (n=48) 
adolescents. 
Sample split into 
discovery and 
validation set




Differential methylation in 23,305 CpGs  between lean 
and obese, Top ranked differentially methylated site mean 
β value of 0.15 in lean, in obese 0.18. Differentially 
methylated sites identified in discovery set can predict 
presence obesity in validation set.
Comparison lean and 
obese 61
Lean (n=24) and 
obese (n=23) 
preadolescent girls
WB 27,000 CpGs/ Illumina 
Infinium HumanMethylation27 
BeadChip
Differential methylation in 20 sites between the lean and 
obese group, multiple sites in/near transcriptional 
regulator genes. Percentage change in obese relative to 
lean from -16.7 to 15.5 % (P=0.007 to 0.04)
Genome wide approaches
Candidate gene approaches
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Comparison lean and 
obese 63
Lean (n=7) and 
obese (n=7) 
adolescent males 
Validation in 2nd 
cohort (n=92) 
PBL 27,000 CpGs/ Infinium 
HumanMethylation27 
BeadChip, validation of 6 
CpGs by pyrosequencing 
No significant differentially methylated sites after 
multiple testing corrections. Selection of highest 6 
differentially methylated sites for validation. In validation 
step, methylation status of 1 in UBASH3A  was 3.3% 
higher (P=0.002) and in the TRIM3  was 1.21% (P 
<0.001) lower in the obese versus the lean group and 
significant after adjustment for age. 
Association with BMI at 2 
time points 11 yrs apart 64
Adults (n=74) Lymphocytes 4 million CpGs/ CHARM with 
custom designed NimbleGen 
HD2 microarray
Covariation with BMI for variable methylated regions in 
MMP9  (β-coefficient b=11.6, P=0.007), PM20D1 
(b=7.6, P=0.003), PRKG1  (b=11.8, P=0.013) and RFC5 
(b= -11.8, P=0.018), also at 2nd time point. Variable 
methylated regions in or near 9 other genes only 
correlated with BMI at 1st time point. 
Abbreviations: BF%, Body Fat Percentage; CHARM, comprehensive high-throughput arrays for relative methylation; 
CpGs, cytosine-phosphate-guanine sites; DMR, differentially methylated regions; FDR, False Discovery Rate; ICR, Imprinting Control Region; 
MZ, monozygotic; PB, peripheral blood; PBL, peripheral blood leukocytes; WB, whole blood; WC, waist circumference
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Table 3 Intervention studies 
Study design and reference Population Tissue 
type
Methylation sites/method Main findings
Comparison of methylation  








After exercise intervention changes in methylation 
(ranging from 0.2-10.9%)  in 17,975 CpGs in 7,663 
unique genes, including 18 obesity candidate genes. 
Comparison of methylation 
before and 6 months after 
gastric bypass surgery 52
Obese (n=8) and 
matched lean (n=9) 
women, obese men 
(n=6)
Muscle In women PGC1 α 
and PDK4  promoter region 
and 14 other genes. In men 
genome-wide methylation 
analysis /Bisulfite sequencing, 
and methyl-CpG binding 
protein-based system for 
methylated DNA enrichment
After weight loss surgery promoter methylation of PGC-
1α  decreased ( ~2.2% to ~0.8%) and of PDK4 increased 
( ~0.3% to ~1.1%) in obese women, to levels comparable 
with lean women. Among the 14 metabolic genes 
analysed, promoter methylation of 11 genes was 
normalized to levels in lean individuals. In men, 409 
differentially methylated regions after weight loss 
surgery. 
Comparison of methylation 
between low and high 
responders to 10 wk diet and 
exercise weight loss 
intervention 67
Overweight and obese 
adolescents (n=24). 
Validation in n=107




using Sequenom EpiTyper 
MassARRAY
Differential methylation in 97 CpGs  between the low and 
high responders (absolute methylation difference >5%, 
P <0.05). After validation, 5 DMRs in or near AQP9, 
DUSP22, HIPK3, TNNT1 , and TNNI3  showed 
methylation differences between the high and low 
responders and/or correlated with changes in weight
Association between baseline 
methylation and weight loss 




and obese (n=20) 
women
PBL CpGs CLOCK, BMAL1, 
PER2 / Sequenom EpiTyper 
MassARRAY 
Weight loss was associated with baseline methylation 
levels of CLOCK  CpG 1 (r=0.377, P=0.01) and PER2 
CpGs 2-3 (r=0.318, P=0.016) and CpG 25 (r=0.318, 
P=0.016) 
Comparison of methylation 
before and after weight loss 
due to bariatric surgery 123
Severely obese (n=8) SAT 305 bp region in LEP 
promoter, 31 CpGs/ clonal 
bisulfite sequencing
No change in methylation level
Comparison of baseline and 
after intervention methylation 
levels between high responders 
and low responders to 8 wk 
caloric restriction 69
Obese women (n=27) SAT LEP  and TNFA  promoter 
methylation/ Methylation 
specific PCRs
At baseline, responders to the weight loss intervention 
showed lower promoter methylation levels of LEP  than 
the non-responders (~18% vs ~33%, P=0.017). No change 
in methylation of LEP  or TNFA  after intervention.
Comparison of baseline and 
after intervention methylation 
levels between responders and 
low responders to 8 wk caloric 
restriction 66
Overweight or obese 
men (n=6 high 
responders, n=6 non 
responders). 
Validation in the same 
subjects and n=13 
extra 
PBMC >27,000 CpGs/ Illumina 
Infinium 
HumanMethylation27 
BeadChip, validation using 
Sequenom EpiTyper 
MassARRAY 
At baseline, 1034 differentially methylated CpGs between 
high and low responders. Validation of CpGs ATP10A  (3-
9% difference) and CD44  (8% difference). Changes in 
methylation of 170 CpGs as result of intervention. 
Validation of increases in methylation CpGs in WT1 and 
ATP10A, change in methylation associated with change 
in fat mass and BMI.
Comparison of baseline and 
after intervention methylation 
levels between high and low 




women, (n=7 high 
responders, n= 7, low 
responders) 
SAT 14,923 CpGs/ Human CpG-
island 8.1K array and 6800 
additional CpG island loci, 
validation using Sequenom 
EpiTyper MassARRAY
At baseline, 35differentially methylated CpGs between 
high and low responders (fold change -1.32 to 1.44). 
After intervention 3 CpGs differentially methylated (fold 
change 1.18 to 1.38). Some differentially methylated 
genes involved in weight control, insulin secretion and in 
imprinted genomic regions
Abbreviations: CpGs, cytosine-phosphate-guanine sites; FDR, false discovery rate; PBL, peripheral blood leukocytes; 
PBMC, peripheral blood mononuclear cells; SAT subcutaneous adipose tissue; WB, whole blood; WC, waist circumference
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Table 4 DNA methylation at early life; effect of interventions and association with later life obesity 
Study design and 
reference
Population Tissue type Methylation sites Main findings
Association of 
methylation in children 
with maternal BMI 44 
School children 
(n=533) 
PBL Global (LINE1)/ 
pyrosequencing
Children in the lowest category of maternal BMI (<18.5 
kg/m2) had notably lower DNA methylation than those in 
the other three BMI categories  (79.88% ±0.66  vs 
80.27% ± 0.63, 80.27% ±0.67 and  80.29% ±0.71, P= 
Association of 
methylation in cord 
blood with maternal BMI 
74
Mother and child 
pairs (n=319) 
Cord blood Global (LINE1)/ 
pyrosequencing
No association found between maternal prepregnancy 
BMI and LINE1 methylation 
Association of 
methylation in placenta 
with maternal BMI 75
Mother-child pairs 
(n=50)
Placenta IGF2  (DMR0, DMR2) and 
H19 (DMR) 19 CpGs/ 
pyrosequencing
No association found with maternal BMI
Association of 
methylation in newborns 
and obesity of father 73
Newborns (n=79) Cord blood DMRs at IGF2  and H19/ 
pyrosequencing
Methylation at the IGF2  DMR was negatively associated 
with paternal obesity (b= -5.28, P = 0.003)
Comparison of 
methylation in children 
born before and after 
maternal bariatric surgery 
76 77
Mothers (n=20), 
Siblings born before 
(n=25) and after 
(n=25) surgery, age 2-
24 yrs
PBL >480,000 CpGs,Infinium 
HumanMethylation450 
BeadChip, validation using 
Sequenom EpiTyper 
MassARRAY 
Children born before, compared to those born after 
surgery, had higher weight and WC and 14,466 
differentially methylated CpGs in 5698 genes, involved in 
glucose regulation, vascular disease, 
immunity/inflammation. Validation of CADPS2 (Δ 
b=0.09), LAMC3 (Δ b=0.07) and SHANK2 (Δ b=0.06)
Association of 
methylation at birth with 
adiposity at age 10 80
Children (n=178) Cord blood 29 genes, 1–3 sites per gene 
Selection based on gene 
expression comparison of lean 
and obese children/ Illumina 
GoldenGate Cancer Panel I 
array
Methylation in CASP10, CDKN1C, EPHA1, HLA-DOB, 
NID2, MMP9, MPL  was associated with body 
composition at age 9 yrs. No association remained 
significant after multiple testing corrections. 
Association of 
methylation at birth and 
childhood with body 
composition in childhood 
81
Cohort 1: children 
born preterm (n=91) 
Cohort 2: children, 
born term (n=131)
Cohort 1: WB 
at age 11yrs. 
Cohort 2: cord 
blood and WB 
at age 7 yrs
7 CpGs in TACSTD2/ 
pyrosequencing 
In cohort 1, mean TACSTD2  methylation was negatively 
correlated with fat mass at age 11 (r=-0.22, P=0.037). In 
cohort 2, TACSTD2  methylation in cord blood  was 
positively correlated (r=0.20, P=0.040) with fat mass  at 
age 15, similar pattern at age 7 yrs, no association at age 9 
yrs
Association of  
methylation at birth with 
adiposity at age 9 79
Children (n=78), 
Validation in 2nd 
child cohort (n=239)
Cord tissue 5 candidate genes (RXRA 
eNOS, SOD1, IL8, PI3KCD ), 
68 CpGs/ pyrosequencing
Sex-adjusted childhood fat mass was associated with 
methylation in RXRA  (exponentiated b= 17% per  SD 
change in methylation, 95% CI: 4–31, P = 0.009) and in 
eNOS  (exponentiated b = 20%, 95% CI: 9–32, P = 0.001) 
at birth. RXRA  methylation and sex explained 26% of the 
var iance in childhood fat mass. Validation of association 
between RXRA  methylation and fat mass in 2nd cohort. 
Association of 
methylation at birth with 
weight for age at 1 yrs78
Children (n=204) Cord blood IGF2 DMR 3 CpGs, H19 
DMR 4 CpGs/ 
pyrosequencing
Methylation level of H19  DMR at birth is 3.4% higher in 
overweight or obese children compared to normal weight 
children at age 1 yrs (P= 0.003)
Abbreviations: CpGs, cytosine-phosphate-guanine sites; DMR, differentially methylated region; PBL, peripheral blood leukocytes; WB, whole blood
Parental intervention and DNA methylation
Early life DNA methylation and later life adiposity
Parental BMI and early life DNA methylation
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